Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
826 stopped studies mapped to Malignant Female Reproductive System Neoplasm and descendants · 86% state a reason
Over the 826 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01958580 | Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With… | N/A | terminated | Oct 9, 2013 | Albert Einstein College of Medicine | Study terminated due to low accrual. PI left the institution | Investigator |
| NCT05365243 | A Pilot Study to Evaluate the Use of the AMMA Portable Scalp Cooling System From Cooler… | N/A | withdrawn | May 9, 2022 | Cooler Heads Care Inc. | Single-site study, site was unable to participate | Other (stated, no rule matched) |
| NCT00794339 | Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer(ACRIN6682) | Phase 2 | terminated | Nov 20, 2008 | American College of Radiology | transfer of funding | Funding |
| NCT04066894 | Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal… | Phase 2 | terminated | Aug 26, 2019 | M.D. Anderson Cancer Center | Due to Issues Enrolling Patients | Enrollment / accrual |
| NCT05026502 | A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of…(REACH) | — | terminated | Aug 30, 2021 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT00968799 | Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A… | N/A | terminated | Aug 31, 2009 | Cantonal Hospital of St. Gallen | poor patient accrual | Enrollment / accrual |
| NCT02059265 | Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube,… | Phase 2 | terminated | Feb 11, 2014 | National Cancer Institute (NCI) | Interim monitoring | Other (stated, no rule matched) |
| NCT02341118 | Capturing BRCA1/2 Mutational Status in Women With High Grade Serous Ovarian Cancer and… | — | terminated | Jan 19, 2015 | University Health Network, Toronto | This study did not collect sufficient data for primary endpoint analysis. | Other (stated, no rule matched) |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid… | Phase 1 / Phase 2 | terminated | Jun 11, 2020 | Genmab | Study was terminated due to MTD was reached | Other (stated, no rule matched) |
| NCT05584332 | A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV… | Phase 3 | terminated | Oct 18, 2022 | Shanghai Bovax Biotechnology Co., Ltd. | Strategic adjustment | Sponsor / business decision |
| NCT00788125 | Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With… | Phase 1 / Phase 2 | terminated | Nov 10, 2008 | City of Hope Medical Center | Terminated early due a shift in resources after lackluster performance of the drug. | Other (stated, no rule matched) |
| NCT00298064 | Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer | N/A | withdrawn | Mar 1, 2006 | University of New Mexico | not stated | Not stated |
| NCT04163094 | Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With…(OLIVIA) | Phase 1 | terminated | Nov 14, 2019 | University Medical Center Groningen | Despite the extension of the original recruitment period, the target number of evaluable patients… | Enrollment / accrual |
| NCT05614453 | Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer…(ITTACC) | Phase 2 | withdrawn | Nov 14, 2022 | Australia New Zealand Gynaecological Oncology Group | BeiGene has withdrawn their support owing to sitravatinib supply concerns. Mirati is ceasing… | Drug supply |
| NCT01992861 | MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA… | — | terminated | Nov 25, 2013 | University of Washington | not stated | Not stated |
| NCT01133756 | E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine… | Phase 1 / Phase 2 | terminated | May 31, 2010 | Eisai Inc. | poor accrual | Enrollment / accrual |
| NCT05431582 | Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and… | Phase 1 | withdrawn | Jun 24, 2022 | M.D. Anderson Cancer Center | No participants enrolled | Enrollment / accrual |
| NCT03824704 | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected… | Phase 2 | terminated | Jan 31, 2019 | pharmaand GmbH | Sponsor made a business decision to discontinue the study due to low accrual. | Enrollment / accrual |
| NCT04510584 | Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer | Phase 2 | withdrawn | Aug 12, 2020 | University Health Network, Toronto | 19 patients screenfailed, stopping recruitment before first patient enrollment to analyze pilot… | Enrollment / accrual |
| NCT05736952 | Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent… | Phase 2 | withdrawn | Feb 21, 2023 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Program changed | Other (stated, no rule matched) |
| NCT05368506 | ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian… | Early Phase 1 | withdrawn | May 10, 2022 | OHSU Knight Cancer Institute | PI discretion | Other (stated, no rule matched) |
| NCT03400943 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3) | Phase 3 | terminated | Jan 17, 2018 | Bayer | Due to a change in the development program, the study was closed prematurely. | Other (stated, no rule matched) |
| NCT04073485 | Microwave Ablation for Uterine Fibroids | N/A | terminated | Aug 29, 2019 | Chinese University of Hong Kong | poor patient accrual | Enrollment / accrual |
| NCT03642990 | NR in Chemo-induced Peripheral Neuropathy | Phase 2 | terminated | Aug 22, 2018 | Donna Hammond, PhD | Enrollment challenges | Enrollment / accrual |
| NCT03642132 | Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100) | Phase 3 | terminated | Aug 22, 2018 | Pfizer | Phase 3 B9991010 study was stopped due to futility of efficacy at interim analysis on 21Dec2018,… | Efficacy / futility |
| NCT02291055 | A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human… | Phase 1 / Phase 2 | terminated | Nov 14, 2014 | Advaxis, Inc. | not stated | Not stated |
| NCT02853604 | Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer(AIM2CERV) | Phase 3 | terminated | Aug 3, 2016 | Advaxis, Inc. | not stated | Not stated |
| NCT05419817 | Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors… | Phase 2 | withdrawn | Jun 15, 2022 | Haider Mahdi | Slow Accrual | Enrollment / accrual |
| NCT05506800 | Guangzhou Women's Health Cohort Study (GWHCS) | — | suspended | Aug 18, 2022 | Guangzhou Women and Children's Medical Center | Due to the rebound of the COVID-19 epidemic in the city, we have to suspend the project temporarily. | COVID-19 / pandemic |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies -… | Phase 1 / Phase 2 | terminated | Mar 19, 2015 | Incyte Corporation | not stated | Not stated |
| NCT03933813 | Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients | Phase 1 / Phase 2 | terminated | May 1, 2019 | University of Wisconsin, Madison | slow accrual | Enrollment / accrual |
| NCT00849667 | Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and… | Phase 3 | terminated | Feb 24, 2009 | Morphotek | Lack of efficacy | Efficacy / futility |
| NCT02607813 | Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway… | Phase 1 | terminated | Nov 18, 2015 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT04042116 | A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | Phase 1 / Phase 2 | suspended | Aug 1, 2019 | Clovis Oncology, Inc. | Company decision | Sponsor / business decision |
| NCT04851834 | NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based… | Phase 1 / Phase 2 | terminated | Apr 20, 2021 | Xennials Therapeutics Australia Pty Ltd | Study was terminated by IP Holder (collaborator), PinotBio Inc. | Other (stated, no rule matched) |
| NCT05393635 | ITIL-168 in Advanced Solid Tumors(DELTA-2) | Phase 1 | withdrawn | May 26, 2022 | Instil Bio | business decision | Sponsor / business decision |
| NCT02978222 | Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With… | Phase 2 | terminated | Nov 30, 2016 | Marker Therapeutics, Inc. | Futility analysis did not support continuation of the trial | Efficacy / futility |
| NCT05062174 | Breast Cancer BRCA1 Carriers: a Pilot Study | — | withdrawn | Sep 30, 2021 | Indiana University | PI decision to cancel research | Other (stated, no rule matched) |
| NCT04672980 | RTX-321 Monotherapy in Patients With HPV 16+ Tumors | Phase 1 | terminated | Dec 17, 2020 | Rubius Therapeutics | The Sponsor terminated study after dosing 3 dose groups (9 pts) and closed trial on 11/30/22.… | Other (stated, no rule matched) |
| NCT04294836 | Curcumin in Advanced Cervical Cancer | Phase 2 | withdrawn | Mar 4, 2020 | Instituto Nacional de Cancerologia, Columbia | Issues with local regulatory authority | Other (stated, no rule matched) |
| NCT03801031 | Sexual Dysfunction in Gynecologic Oncology Patients | Phase 4 | terminated | Jan 11, 2019 | David Bender | Slow accrual | Enrollment / accrual |
| NCT04762225 | RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors… | Phase 1 | terminated | Feb 21, 2021 | Repertoire Immune Medicines | Development program terminated | Other (stated, no rule matched) |
| NCT05061940 | This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status… | — | terminated | Sep 30, 2021 | Repertoire Immune Medicines | Development program terminated | Other (stated, no rule matched) |
| NCT02933073 | Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma | Phase 1 | terminated | Oct 14, 2016 | UConn Health | Study recruitment is temporary on hold by the sponsor due to patient recruitment challenges and the… | Enrollment / accrual |
| NCT03693846 | Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors | Phase 2 | terminated | Oct 3, 2018 | Abramson Cancer Center at Penn Medicine | Terminated due to slow enrollment and lack of efficacy | Efficacy / futility |
| NCT04368130 | SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care(SIGNAL) | N/A | withdrawn | Apr 29, 2020 | Dana-Farber Cancer Institute | The anomaly detection system is still under development and is not ready to test. | Other (stated, no rule matched) |
| NCT04943627 | Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical… | Phase 3 | withdrawn | Jun 29, 2021 | Agenus Inc. | Strategic Business Decision | Sponsor / business decision |
| NCT00373217 | Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing… | Phase 2 | terminated | Sep 7, 2006 | Craig L Slingluff, Jr | Slow enrollment rate. | Enrollment / accrual |
| NCT02203513 | A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation… | Phase 2 | terminated | Jul 30, 2014 | National Cancer Institute (NCI) | Eli Lilly prematurely terminated the study. | Other (stated, no rule matched) |
| NCT02601209 | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or… | Phase 1 / Phase 2 | terminated | Nov 10, 2015 | National Cancer Institute (NCI) | Interim monitoring | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 16, 2023source: clinicaltrials